The Pharmacology of (-)-Nicotine and Novel Cholinergic Channel Modulators

Advances in Pharmacology

Volumn 37, Issue C, 1996, Pages 153-214

  Brioni, Jorge D ^a   Decker, Michael W ^a   Sullivan, James P ^a   Arneric, Stephen P ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0343378913     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60950-3     Document Type: Article

References (262)

1. 3H]Methylcarmamylcholine, a new radioligand for studying brain nicotinic receptors. Biochem. Pharmacol. 35 (1986) 4199-4202
2. Abood L.G., Reynolds D.T., Booth H., and Bidlack J.M. Sites and mechanisms for nicotine's action in the brain. Neurosci. Biobehav. Rev. 5 (1981) 479-486
3. Abreo M., Lin N., Garvey D., Gunn D., Hettinger A., Wasicak J.T., Pavlik P., Martin Y., Sullivan J., Williams M., Arneric S., and Holladay M. Novel 3-pyridil ethers with subnanomolar affinity for central nicotinic acetylcholine receptors. J. Med. Chem. 39 (1996) 817-825
4. Adem A., Nordberg A., Sukhwinder S.J., Sara S., and Gillberg P.G. Quantitative autoradiography of nicotinic receptors in large cryosections of human brain hemispheres. Neurosci. Lett. 101 (1989) 247-252
5. Adler L., Pachtman E., Franks R., Pecevich M., Waldo M., and Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol. Psychiatry 17 (1982) 639-644
6. Adler L., Hoffer L., Griffith J., Waldo M., and Freedman R. Normalization by nicotine of deficient auditory sensory gating in relatives of schizophrenics. Biol. Psychiatry 32 (1992) 607-616
7. Aizenman E., Tang L., and Reynolds I. Effects of nicotinic agonists on the NMDA receptor. Brain Res. 551 (1991) 355-357
8. Akaike A., Tamura Y., Yokaota T., Shimohama S., and Kimura J. Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 644 (1994) 181-187
9. Alkondon M., Reinhardt S., Lobron C., Hermsen B., Maelicke A., and Albuquerque E. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. II. The rundown and inward rectification of agonist elicited whole cell currents and identification of receptor subunits by in situ hybridization. J. Pharmacol. Exp. Ther. 271 (1994) 494-506
10. Anand R., Peng X., Ballesta J., and Lindstom J. Pharmacological characterization of α-bungarotoxin-sensitive acetylcholine receptors immunoisolated from chick retina: Contrasting properties of α7 and α8 subunit containing subtypes. Mol. Pharmacol. 44 (1993) 1046-1050
11. Andersen P., Bliss T.V.P., and Skrede K.K. Lamellar organization of hippocampal excitatory pathways. Exp. Brain Res. 13 (1971) 222-238
12. 3H]methylcarbamylcholine in rat brain. Eur. J. Pharmacol. 253 (1994) 261-267
13. 3H]ABT-418: A novel cholinergic channel ligand. J. Pharmacol. Exp. Ther. 237 (1995) 1434-1441
14. Arendash G.W., Sengstock G.J., Sanberg P.K., and Kem W.R. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res. 674 (1995) 252-259
15. Arneric S.P., Anderson D., Bannon A., Briggs C., Brioni J., Decker M., Donnelly-Roberts D., Gopalakrishnan M., Holladay M., Kyncl J., Marsh K., Pauly J., Radek R., Rodriguez D., and Sullivan J. Preclinical pharmacology of ABT-418: A prototypical cholinergic channel activator for the potential treatment of Alzheimer's disease. CNS Drugs Rev. 1 (1995) 1-26
16. Arneric S.P., Sullivan J.P., Briggs C.A., Donnelly-Roberts D., Anderson D.J., Raszkiewicz J.L., Hughes M., Cadman E.D., Adams P., Garvey D.S., Wasicak J., and Williams M. ABT 418: A novel cholinergic ligand with cognition enhancing and anxiolytic activities: I. In vitro characterization. J. Pharmacol. Exp. Ther. 270 (1994) 310-318
17. Arneric S.P., Sullivan J.P., Decker M.W., Brioni J.D., Bannon A.W., Briggs C.A., Donnelly-Roberts D., Radek R.J., Marsh K.C., Kyncl J., Williams M., and Buccafusco J.J. Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties. Alzheimer Dis. Associated Disord. 9 (1995) 50-61
18. Arneric S.P., Sullivan J., and Williams M. Neuronal nicotinic acetylcholine receptors: Novel targets for CNS therapeutics. In: Bloom F., and Kupfer D. (Eds). "Psychopharmacology: Fourth Generation of Progress" (1995), Raven Press, New York 95-110
19. Austin M.C., and Kalivas P.W. The effect of cholinergic stimulation in the nucleus accumbens on locomotor behavior. Brain Res. 411 (1988) 209-214
20. Badio B., and Daly J.W. Epibatidine, a potent analgetic and nicotinic agonist. Mol. Pharmacol. 45 (1994) 563-569
21. Balfour D. The influence of stress on psychopharmacologica1 responses to nicotine. Br. J. Addict. 86 (1991) 489-493
22. Balfour D., Graham C., and Vale A. Studies on the possible role of brain 5-HT systems and adrenocortical activity in behavioural responses to nicotine and diazepam in an elevated X-maze. Psychopharmacology 90 (1986) 528-532
23. Bannon A.W., Gunther G.L., and Decker M.W. Is epibatidine really analgesic? Dissociation of the locomotor activity, temperature, and analgesic effects of (±)-epibatidine. Pharmacol. Biochem. Behav. 51 (1995) 693-698
24. Bannon A.W., Gunther K.L., Decker M.W., and Arneric S.P. The influence of Bay K 8644 treatment of (±)-epibatidine-induced analgesia. Brain Res. 678 (1995) 244-250
25. Bartus R.T., Dean R.L., Beer B., and Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-417
26. 3H]-acetylcholine release from cortical slices of guinea-pig brain. Naunyn Schmiedebergs Arch. Pharmacol. 331 (1985) 293-296
27. 3H]-D-aspartate and endogenous GABA in freely moving guinea-pigs. Br. J. Pharmacol. 104 (1991) 15-20
28. Benwell M.E.M., and Balfour D.J.K. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br. J. Phamracol. 105 (1992) 849-856
29. Bernston G., Beattie M., and Walker J. Effects of nicotinic and muscarinic compounds on biting attack in the cat. Pharmacol. Biochem. Behav. 5 (1976) 235-239
30. Bertrand D., Bertrand S., and Ballivet M. Pharmacological properties of the homomeric α7 receptor. Neurosci. Lett. 146 (1992) 87-90
31. Betz H. Ligand-gated ion channels in the brain: The amino acid receptor superfamily. Neuron 5 (1990) 383-392
32. Biederman J., Faraone S., Spencer T., Wilens T., Norman D., Lapey K., Mick E., Lehman B., and Doyle A. Patterns of pyschiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry 150 (1993) 1792-1798
33. Briggs C., Anderson D., Brioni J., Buccafusco J., Campbell J., Decker M., Donnelly-Roberts D., Gopalakrishnan M., Holladay M., Sullivan J., and Arneric S. Functional characterization of the novel nicotinic receptor ligand GTS-21 in vivo and in vitro. Pharmacol. Biochem. Behav. (1996) In press
34. Briggs C.A., McKenna D.G., and Piattoni-Kaplan M. Human α7 nicotinic acetylcho-line receptor responses to novel ligands. Neuropharmacology 34 (1995) 583-590
35. Brioni J.D. Role of GABA during the multiple consolidation of memory. Drug Dev. Res. 28 (1993) 3-27
36. Brioni J.D., and Arneric S.P. Nicotinic receptor agonists facilitate retention of avoidance training: Participation of dopaminergic mechanisms. Behav. Neural Biol. 59 (1993) 57-62
37. Brioni J.D., Decker M., Sullivan J., and Arneric S.P. Preclinical pharmacology of the novel cholinergic channel activator ABT-418 (1995), Nicotine Symposium, Fourth International Behavioral Neuroscience Conference, Santiago, Spain.
38. Brioni J.D., Kim D.B.J., Brodie M.S., Decker M.W., and Arneric S.P. ABT-418: Discriminative stimulus properties and effect on ventral tegmental cell activity. Psychopharmacology 107 (1995) 368-375
39. Brioni J.D., Kim D., and O'Neill A. Nicotine cue: Lack of effect of the α7 nicotinic receptor antagonist methyllycaconitine. Eur. J. Pharmacol. (1996) In press
40. Brioni J.D., Kim D.J.B., O'Neill A.B., Williams J.E.G., and Decker M.W. Clozapine attenuates the discriminative stimulus properties of (-)-nicotine. Brain Res. 643 (1994) 1-9
41. Brioni J.D., Linville D.G., Cadman E.D., Buckley M., Anderson D.J., and Arneric S.P. Classical nicotinic agonists differentially affect cognition, cortical cerebral blood flow and dopamine release. Soc. Neurosci. Abstr. 17 (1991) 1236
42. Brioni J.D., O'Neill A., Kim D.J.B., and Decker M.W. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze. Eur. J. Pharmacol. 238 (1993) 1-8
43. Brioni J.D., O'Neill A.B., Kim D.J.B., Decker M.W., and Arneric S.P. Anxiolytic-like effects of the novel cholinergic channel activator ABT 418. J. Pharmacol. Exp. Ther. 271 (1994) 353-361
44. Brucato F.H., Levin E.D., Rose J.E., and Swartzwelder H.S. Intracerebroventricular nicotine and mecamylamine alter radial-arm maze performance in rats. Drug Dev. Res. 31 (1994) 18-23
45. Buccafusco J., and Jackson W. Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol. Aging 12 (1991) 233-238
46. Buccafusco, J. J., Jackson, W. J., Gattu, M., and Terry, A. V., Jr. (1996). Isoarecolone-induced memory enhancement in monkeys: Role of nicotinic receptors.
47. Buccafusco J., Jackson W., Terry A., Marsh K., Decker M., and Arneric S. Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: A novel cholinergic channel activator for memory enhancement. Psychopharmacology 120 (1995) 256-266
48. Cao W.U., Burkholder T., Wilkins L., and Collins A.C. A genetic comparison of behavioral actions of ethanol and nicotine in the mirrored chamber. Pharmacol. Biochem. Behav. 45 (1993) 803-809
49. Changeux J., Galzi J., Devillers-Thiery A., and Betrand D. The functional architecture of the acetylcholine nicotinic receptor explored by affinity labeling and site-directed mutagenesis. Q. Rev. Biophys. 25 (1992) 395-432
50. Choi D.W., and Rothman S.M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 13 (1990) 171-182
51. Cimino M., Marini P., Fornasari D., Cattabeni F., and Clementi F. Distribution of nicotinic receptors in cynomolgus monkey brain and ganglia: Localization of alpha 3 subunit mRNA, alpha-bungarotoxin and nicotine binding sites. Neuroscience 51 (1992) 77-86
52. Clarke P.B.S. Chronic central nicotinic blockade after a single administration of the bisquaternary ganglion-blocking drug chlorisondamine. Br. J. Pharmacol. 83 (1984) 527-535
53. Clarke P.B.S. Dopaminergic mechanisms in the locomotor stimulant effects of nicotine. Biochem. Pharmacol. 40 (1990) 1427-1432
54. Clarke P.B.S. Nicotine dependence-Mechanisms and therapeutic strategies. Biochem. Soc. Symp. 59 (1994) 83-95
55. Clarke P.B.S., and Fibiger H.C. Reinforced alternation performance is impaired by muscarinic but not by nicotinic receptor blockade in rats. Behav. Brain Res. 36 (1990) 203-207
56. 125I]-α-bungarotoxin. J. Neuroscr. 5 (1985) 1307-1315
57. Clarke P.B.S., Fu D.S., Jakubovic A., and Fibiger H.C. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J. Pharmacol. Exp. Ther. 246 (1988) 701-708
58. Connolly J., Boulter J., and Heinemann S.F. α4-β2 and other nicotinic acetylcholine receptor subtypes as targets of psychoactive and addictive drugs. Br. J. Pharmacol. 105 (1992) 657-666
59. Corrigall W., and Coen K. Nicotine maintains robust self-administration in rats on a limited schedule. Psychopharmacology 99 (1989) 473-478
60. Corrigall W., and Coen K. Dopamine mechanisms play at best a small role in the nicotine discriminative stimulus properties. Pharmacol. Biochem. Behav. 48 (1994) 817-820
61. Corrigall W.A., Coen K.M., and Adamson K.L. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res. 653 (1994) 278-284
62. Costall B., Kelly M.E., Naylor R.J., and Onaivi E.S. The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol. Biochem. Behav. 33 (1989) 197-203
63. Courturier S., Bertrand D., Matter J.M., Hernandez M.-C., Bertrand S., Miller N., Valera S., Barkas T., and Ballivet M. A neuronal nicotinic acetylcholine receptor subunit (α:7) is developmentally regulated and forms a homo-oligomeric ion channel blocked by α-BTX. Neuron 5 (1990) 847-856
64. Coyle J., Price D., and DeLong M. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 219 (1983) 1184-1190
65. Curzon P., Brioni J.D., and Decker M.W. Behavioral effects of nicotinic cholinergic receptor (nAChR) blockade with dihydro-β-erythroidine (DHβE) and methyllycaconitine (MLA). Soc. Neurosci. Abstr. 20 (1994) 150
66. Damaj M.I., Welch S.P., and Martin B.R. Involvement of calcium and L-type channels in nicotine-induced antinociception. J. Pharmacol. Exp. Therap. 266 (1993) 1330-1338
67. Damaj M., Creasy K., Rosecrans J., and Martin B. Pharmacological effects of epibatidine optical enantiomers. Brain Res. 664 (1994) 34-40
68. Damaj M.L., Creasy K.R., Welch S.P., Rosecrans J.A., Aceto M.D., and Martin B.R. Comparative pharmacology of nicotine and ABT-418, a new nicotinic agonist. Psychopharmacology 120 (1995) 483-490
69. Damaj M.I., and Martin B.R. Is the dopaminergic system involved in the central effects of nicotine in mice. Psychopharmacology 111 (1993) 106-108
70. Day J., and Fibiger H. Dopaminergic regulation of cortical acetylcholine release. Synapse 12 (1992) 281-286
71. Day J., and Fibiger H. Dopaminergic regulation of cortical acetylcholine release: Effects of dopamine receptor agonist. Neuroscience 54 (1993) 643-648
72. 125I-α- bungarotoxin receptor subtypes. Mol. Pharmacol. 47 (1995) 164-171
73. de Fiebre C.M., Singer J., Bloss N., and Meyer E. Ethanol affects the function of neuronal nicotinic cholinergic receptors expressed in xenopus oocytes. Soc. Neurosci. Abstr. 19 (1993) 1835
74. Decker M.W. Cholinergichoradrenergic interactions and memory. In: Levin E.D., Decker M.W., and Butcher L.L. (Eds). "Neurotransmitter Interactions and Cognitive Function" (1992), Birkhauser, Boston 78-90
75. Decker M.W., Anderson D.J., Brioni J.D., Donnelly-Roberts D.L., Kang C.-H., Piattoni-Paplan M., Swanson S., and Sullivan J.P. Erysodine: A competitive antagonist at neuronal nicotinic acetylcholine receptors. Eur. J. Pharmacol. 280 (1995) 79-89
76. Decker M.W., Brioni J.D., Bannon A.W., and Arneric S.P. Diversity of neuronal nicotinic acetylcholine receptors: Lessons from behavior and implications for CNS therapeutics. Life Sci. 56 (1995) 545-570
77. Decker M.W., Brioni J.D., Sullivan J.P., Buckley M.J., Radek R.J., Raskiewickz J.L., Kang C.H., Kim D.J.B., Giardina W.J., Williams M., and Arneric S.P. (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): A novel cholinergic ligand with cognition enhancing and anxiolytic activities: II. In vivo characterization. J. Pharmacol. Exp. Ther. 270 (1994) 319-328
78. Decker M.W., Curzon P., Brioni J.D., and Arneric S.P. Effects of ABT 418, a novel cholinergic channel ligand, on learning and memory in septal-lesioned rats. Eur. J. Pharmacol. 261 (1994) 217-222
79. Decker M.W., and Majchrzak M.J. Effects of systemic and intracerebroventricular administration of rnecamylamine, a nicotinic cholinergic antagonist, on spatial memory in rats. Psychopharmacology 107 (1992) 530-534
80. Decker M.W., and Majchrzak M.J. Effects of central nicotinic cholinergic receptor blockade produced by chlorisondamine on learning and memory performance in rats. Behav. Neural Biol. 60 (1993) 163-171
81. Decker M.W., Majchrzak M.J., and Anderson D.J. Effects of nicotine on spatial memory deficits in rats with spatial lesions. Brain Res. 572 (1992) 281-285
82. Decker M.W., Majchrzak M.J., and Arneric S.P. Effect of lobeline, a nicotinic receptor agonist, on learning and memory. Pharmacol. Biochem. Behav. 45 (1993) 571-576
83. Dekker A.J., Connor D.J., and Thal L.J. The role of cholinergic projections from the nucleus basalis in memory. Neurosci. Biobehav. Rev. 15 (1991) 299-317
84. Deneris E.S., Connolly J., Rogers S.W., and Duvoisin R. Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. Trends Pharmacol. Sci. 12 (1991) 34-40
85. Dineley-Miller K., and Patrick J. Gene transcripts for the nicotinic acetylcholine receptor subunit, beta4, are distributed in multiple areas of the central nervous system. Mol. Brain Res. 16 (1992) 399-444
86. Dubovsky S. Approaches to developing new anxiolytics and antidepressants. J. Ch. Psychiatry 54 (1993) 75-83
87. Duijn C.V., and Hofman A. Relation between nicotine intake and Alzheimer's disease. Br. Med. J. 302 (1991) 1491-1494
88. Elgoyhen A., Johnson D., Boulter J., Vetter D., and Heinemann S. α9: An acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 79 (1994) 705-715
89. Erenberg E., Cruse R., and Rothner A. The natural history of Tourette syndrome: A follow-up study. Ann. Neurol. 22 (1987) 383-385
90. Ernst M., and Zemetkin A. The interface of genetics, neuroimaging, and neurochemistry in attention-deficit hyperactivity disorder. In: Bloom F.E., and Kupfer D.J. (Eds). "Psychopharmacology: The Fourth Generation of Progress" (1995), Raven Press, New York
91. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., and Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol. 41 (1992) 31-37
92. Freedman R., Wetmore C., Stromberg I., Leonard S., and Olson L. α-Bungarotoxin binding to hippocampal interneurons: Immunocytochemical characterization and effects on growth factor expression. J. Neurosci. 13 (1993) 1965-1975
93. Fung Y.K. The importance of nucleus accumbens in nicotine-induced locomotor acrivity. J. Pharm. Pharmacol. 42 (1990) 595-596
94. Galzi J., Revah F., Bessis A., and Changeux J. Functional architecture of the nicotinic acetylcholine receptor: From electric organ to brain. Annu. Rev. Neurosci. 31 (1991) 37-72
95. Garcha H.S., Thomas P., Spivak C.E., Wonnacott S., and Stolerman I.P. Behavioural and ligand-binding studies in rats with 1-acetyl-4-methylpiperazine, a novel nicotinic agonist. Psychopharmacology 110 (1993) 347-354
96. Garvey D.S., Wasicak J., Decker M.W., Brioni J.D., Sullivan J.P., Carrera G.M., Holladay M.H., Arneric S.P., and Williams M. Novel isoxazoles which interact with brain cholinergic channel receptors that have intrinsic cognitive enhancing and anxiolytic activities. J. Med. Chem. 37 (1994) 1055-1059
97. Gerzanich V., Anand R., and Lindstrom J. Homomers of α8 and α7 subunits of nicotinic receptors exhibit similar channel but contrasting binding site properties. Mol. Pharmacol. 45 (1994) 212-220
98. Gilbert D.G. Paradoxical tranquilizing and emotion-reducing effect of nicotine. Psychol. Bull. 86 (1979) 643-661
99. Gilbert D.G., Robinson J.H., Chamberlin C.L., and Spielberger C.D. Effects of smoking nicotine on anxiety, heart rate and lateralization of EEG during a stressful movie. Psychophysiology 26 (1989) 311-319
100. Goldberg S., Spealman R., and Goldberg D. Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science 214 (1981) 573-575
101. Golden G. Tardive dyskinesia in Tourette syndrome. Pediatr. Neurol 1 (1985) 192-194
102. Gopalakrishnan M., Busisson M., Touma E., Giordano T., Campbell J., Hu I., Bertrand D., Donnelly-Roberts D., Arneric S., and Sullivan J. Pharmacological characterization of the human α7 neuronal nicotinic acetylcholine receptor subtype stably expressed in a mammalian cell line. Eur. J. Pharmacol. 290 (1995) 237-246
103. Gopalakrishnan M., Monteggia L.M., Anderson D.J., Arneric S.P., and Sullivan J.P. Stable expression, pharmacologic properties and regulation of the human nicotinic acetylcholine α4β2 receptor. J. Pharmacol. Exp. Ther. 276 (1996) 289-297
104. 3H]-dopamine release from synaptosomes prepared from mouse striatum. J. Neurochem. 59 (1992) 848-856
105. Granon S., Poucet B., Thinus-Blanc C., Changeux J.P., and Vidal C. Nicotinic and muscarinic receptors in the rat prefrontal cortex: Differential roles in working memory, response selection and effortful processing. Psychopharmacology 119 (1995) 139-144
106. Gray J.A., and McNaughton N. Comparison between the behavioural effects of septal and hippocampal lesions: A review. Neurosci. Biobehav. Rev. 7 (1982) 119-188
107. Gray J.A., Mitchell S.N., Joseph M.H., Grigoryan G.A., Dawe S., and Hodges H. Neurochemical mechanisms mediating the behavioral and cognitive effects of nicotine. Drug Dev. Res. 31 (1994) 3-17
108. Grigoryan G.A., Mitchell S.N., Hodges H., Sinden J.D., and Gray J.A. Are the cognitive-enhancing effects of nicotine in the rat with lesions to the forebrain cholinergic projections system mediated by an interaction with the noradrenergic system. Pharmacol. Biochem. Behav. 49 (1994) 511-521
109. Haman S., and Martin W. Opioid and nicotinic analgesic and hyperalgesic loci in the rat brain stem. J. Pharmacol. Exp. Therap. 261 (1992) 707-715
110. Haroutunian V., Barnes E., and Davies K.L. Cholinergic modulation of memory in rats. Psychopharmacology 87 (1985) 266-271
111. Henningfield J., and Goldberg S. Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol. Biochem. Behav. 19 (1983) 989-992
112. Hirschhorn I., and Rosecrans J. Studies on the time course and the effect of cholinergic and adrenergic receptor blockers on the stimulus effect of nicotine. Psychopharmacologia 40 (1974) 109-120
113. Hodges H., Allen Y., Sinden J., Mitchell S.N., Arendt T., Lantos P.L., and Gray J.A. The effects of cholinergic drugs and cholinergic-rich foetal neural transplants on alcohol-induced deficits in radial maze performance in rats. Behav. Brain Res. 43 (1991) 7-28
114. Hughes J., Hatsukami D.K., Mitchell J., and Dahlgren L. Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry 143 (1986) 989-992
115. Hutchinson R.R., and Emley G.S. Effects of nicotine on avoidance, conditioned suppression and aggression response measures in animals and man. In: Dunn W.L. (Ed). "Smoking Behavior: Motives and Incentives" (1973), V. H. Winston & Sons, Washington, DC. 171-196
116. Ishikawa A., and Miyatake T. Effects of smoking in patients with early-onset Parkinson's disease. J. Neurol. Sci. 117 (1993) 28-32
117. Jackson W.J., Elrod K., and Buccafusco J.J. Delayed matching-to-sample in monkeys as a model for learning and memory deficits: Role of brain nicotinic receptors. In: Meyer E.M., Simpkins J.W., and Yamamoto J. (Eds). "Novel Approaches to the Treatment of Alzheimer's Disease" (1989), Plenum Publishing Corporation, New York 39-52
118. Janson A., and Moller A. Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodiencephalic hemitransection: An analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience 57 (1993) 931-941
119. Jones G.M.M., Sahakian B.J., Levy R., Warburton D.M., and Gray J.A. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 108 (1992) 485-494
120. Khan I., Taylor P., and Yaksh T. Cardiovascular and behavioral responses to nicotinic agents administered intrathecally. J. Pharmacol. Exp. Ther. 270 (1994) 150-158
121. Kim D.J.B., and Brioni J.D. Modulation of the discriminative stimulus properties of (-)-nicotine by ethanol and diazepam. Drug Dev. Res. 34 (1995) 47-54
122. Ksir C., Hakan R.L., and Kellar K.J. Chronic nicotine and locomotor activity: Influences of exposure dose and test dose. Psychopharmacology 92 (1987) 25-29
123. Kumar R., Reavill C., and Stolerman I. Nicotine cue in rats: Effects of central administration of ganglion-blocking drugs. Brit. J. Pharmacol. 90 (1987) 239-246
124. Lena C., and Changeux J.P. Allosteric modulations of the nicotinic acetylcholine receptor. Trends Neurosci. 16 (1993) 181-186
125. Levin E.D. Nicotinic systems and cognitive function. Psychopharmacology 108 (1992) 417-431
126. Levin E.D., Briggs S.J., Christopher N.C., and Auman J.T. Working memory performance and cholinergic effects in the ventral tegmental area and substantia nigra. Brain Res. 657 (1994) 165-170
127. Levin E.D., Castonguay M., and Ellison G.D. Effects of the nicotinic receptor blocker, mecamylamine, on radial-arm maze performance in rats. Behav. Neural Biol. 48 (1987) 206-212
128. Levin E.D., Lee C., Rose J.E., Rcyes A., Ellison G., Jarvik M., and Gritz E. Chronic nicotine and withdrawal effects on radial-arm maze performance in rats. Behav. Neural Biol. 53 (1990) 269-276
129. Levin E.D., McGurk S.R., Rose J.E., and Butcher L.L. Cholinergic-dopaminergic interactions in cognitive performance. Behav. Neural Biol. 54 (1990) 271-329
130. Lippiello P.M., Bencherif M., and Prince R.J. The role of desensitization in CNS nicotinic receptor function. In: Clarke P.B.S., Quik M., Adlkofer F., and Thurau K. (Eds). "Effects of Nicotine on Biological Systems 11" (1995), Birkhauser Verlag, Basel 79-85
131. Lloyd G., McDonald I., Vernier J., Elliott K., Ellis S., Sacaan A., Rao T., Chavez-Noriega L., Johnson E., Velicelebi F., Mengaghi F., and Harpold M. Subtype-selective cholinergic ion channel agonists as potential antiparkinson agents. "The Cholinergic Synapse: Structure, Function and Regulation," (1994), Baltimore 45
132. Loring R. Agmatine acts as an antagonist of neuronal nicotinic receptors. Br. J. Pharmacol. 99 (1990) 207-211
133. Luetje C., and Patrick J. Both α- and β-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J. Neurosci. 11 (1991) 837-845
134. Lukas R.J. Expression of ganglia-type nicotinic acetylcholine receptors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal cell line. J. Pharmacol. Exp. Ther. 265 (1993) 294-302
135. Luntz-Leybman V., Bickford P., and Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res. 587 (1992) 130-136
136. Marin P., Maus M., Desagher S., Glowinski J., and Premont J. Nicotine protects cultured striatal neurons against N-methyl-D-aspartate receptor-mediated neurotoxicity. Neuro Report 5 (1994) 1977-1980
137. Marks M.J., Farnham D.A., Grady S.R., and Collins A.C. Nicotinic receptor function determined by stimulation of rubidium efflux from mouse synaptosomes. J. Pharmacol. Exp. Ther. 264 (1993) 542-552
138. Marks M.J., Stitzel J.A., Romm E., Wehner J.M., and Collins A.C. Nicotinic binding sites in rat and mouse brain: Comparison of acetylcholine, nicotine, and α-bungarotoxin. Mol. Pharmacol. 30 (1986) 427-436
139. Martin E., Panickar K., King M., Deyrup M., Hunter B., Wang G., and Meyer E. Cytoprotective actions of 2,4-dimethoxybenzylidene anabaseine in differentiated PC12 cells and septa1 cholinergic neurons. Drug Dev. Res. 31 (1994) 135-141
140. McConville B., Fogelson M., Klykylo W., Manderscheid P., Parder K., and Sanberg P. Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder. Am. J. Psychiatry 148 (1991) 793-794
141. McDonough Jr. J.H., and Shih T.M. A study of the N-methyl-D-aspartate antagonistic properties of anticholinergic drugs. Pharmacol. Biochem. Behav. 51 (1995) 249-253
142. McGehee D.S., and Role L.W. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu. Rev. Physiol. 57 (1995) 521-546
143. Meltzer L., Rosecrans J., Aceto M., and Harris L. Discriminative stimulus properties of the optical isomers of nicotine. Psychopharmacology 68 (1980) 283-286
144. Meyer E.M., de Fiebre C.M., Hunter B.E., Simpkins C.E., Frauworth N., and de Fiebre N.E.C. Effects of anabaseine-related analogs on rat brain nicotinic receptor binding and on avoidance behaviors. Drug Dev. Res. 31 (1994) 127-134
145. 3H]substance P to the nicotinic acetylcholine receptor of Torpedo electroplaque. Mol. Pharmacol. 45 (1994) 221-227
146. Mitchell S.N. Role of the locus coeruleus in the noradrenergic response to a systemic administration of nicotine. Neuropharmacology 32 (1993) 937-949
147. Moulton B.A., Thinschmidt J.S., Quintana R., Meyer E.M., and Papke R.L. The pharmacology of epibatidine and ABT-418 on putative subtypes of rat neuronal nicotinic receptors. Mol. Pharmacol. (1996) In press
148. Muir J.L., Everitt B.J., and Robbins T.W. Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron. Psychopharmacology 118 (1995) 82-92
149. Museo E., and Wise R.A. Microinjections of a nicotinic agonist into dopamine terminal fields: Effects on locomotion. Pharmacol. Biochem. Behav. 37 (1990) 113-116
150. Museo E., and Wise R.A. Locomotion induced by ventral tegmental microinjections of a nicotinic agonist. Pharmacol. Biochem. Behav. 35 (1990) 735-737
151. Museo E., and Wise R.A. Sensitization of locomotion following repeated ventral tegmental injections of cytisine. Pharmacol. Biochem. Behav. 48 (1994) 521-524
152. Newhouse P.A., Potter A., Corwin J., and Lenox R. Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology 108 (1992) 480-484
153. Newhouse P.A., Potter A., Corwin J., and Lenox R. Modeling the nicotinic receptor loss in dementia using the nicotinic antagonist mecamylamine: Effects on human cognitive functioning. Drug Dev. Res. 31 (1994) 71-79
154. Newhouse P.A., Sunderland T., Tariot P.N., Blumhardt C.L., Weingartner H., Mellow A., and Murphy D.L. Intravenous nicotine in Alzheimer's disease: A pilot study. Psychopharmacology 95 (1988) 171-175
155. Nitta A., Katono Y., Itoh A., Hasegawa T., and Nabeshima T. Nicotine reverses scopolamine-induced impairment of performance in passive avoidance task in rats through its action on the dopaminergic neuronal system. Pharmacol. Biochem. Behav. 49 (1994) 807-812
156. 3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett. 72 (1986) 115-119
157. Oades R. Attention deficit disorder with hyperactivity (ADDH): The contribution of catecholaminergic activity. Prog. Neurobiol. 29 (1987) 365-391
158. O'Farrell T., Connors G., and Upper D. Addictive behaviors among hospitalized schizophrenic patients. Addict. Behav. 8 (1983) 329-333
159. Ohno M., Yamamoto T., and Watanabe S. Blockade of hippocampal nicotinic receptors impairs working memory but not reference memory in rats. Pharmacol. Biochem. Behav. 45 (1993) 89-93
160. Oliverio A. Effects of mecamylamine on avoidance conditioning and maze learning of mice. J. Pharmacol. Exp. Ther. 154 (1966) 350-356
161. Onaivi E., Payne S., Brock J., Hamdi A., Faroouqui S., and Prasad C. Chronic nicotine reverses age-associated increases in tail-flick latency and anxiety in rats. Life Sci. 54 (1994) 193-202
162. O'Neill M.F., Dourish C.T., and Iversen S.D. Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats. Psychopharmacology 104 (1991) 343-350
163. Owman C., Fuxe K., Jason A., and Kahrstrom J. Studies of protective actions of nicotine on neuronal and vascular functions in rats: Comparison between sympathetic noradrenergic and mesostriatal dopaminergic fiber system, and the effect of a dopamine agonist. Prog. Brain Res. 79 (1989) 267-276
164. 3H]Cytisine binding to nicotinic cholinergic receptors in brain. Mol. Pharmacol. 39 (1991) 9-12
165. Papke R. The kinetic properties of neuronal nicotinic receptors: Genetic basis of functional diversity. Prog. Neurobiol. 41 (1993) 509-531
166. Papke R.L., Boulter J., Patrick J., and Heinemann S. Single channel currents of rat neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. Neuron 3 (1989) 589-596
167. Papke R.L., de Fiebre C.M., Moulton B.A., Thinschmidt J.S., Quintana J.S., and Meyer E.M. Activation and inhibition of neuronal nAChRs by potential therapeutic agents. Soc. Neurosci. Abstr. 21 (1995) 247 14
168. Papke R.L., and Heinemann S.F. The role of the β4 subunit in determining the kinetic properties of rat neuronal nicotinic acetylcholine α3-receptor. J. Physiol. (Lond.) 440 (1991) 95-112
169. Papke R.L., and Heinemann S.F. Partial agonists properties of cytisine on neuronal nicotinic receptors containing the beta2 subunit. Mol. Pharmacol. 45 (1993) 142-149
170. Pereira E.F.R., Alkondon M., Tano T., Castro N.G., Froes-Ferraro M.M., Rozental R., Aronstam R.S., Schrattenholz A., Maelicke A., and Albuquerque E.X. A novel agonist binding site on nicotinic acetylcholine receptors. J. Rec. Res. 13 (1993) 413-436
171. Pereira E.F.R., Reinhardt-Maelicke S., Schrattenholz A., Maelicke A., and Albuquerque E. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J. Pharmacol. Exp. Ther. 265 (1993) 1474-1491
172. Pert A. Cholinergic and catecholaminergic modulation of nociceptive reactions. In: Alkil H., and Lewis J. (Eds). "Pain and Headache" (1987), S. Karger, Basel 1-63
173. Philips H., Hains J., Laramee G., Rosenthal A., and Winslow J. Widespread expression of BDNF but not NT-3 by target areas of basal forebrain cholinergic neurons. Science 250 (1990) 290-294
174. Picciotto M.R., Zoll M., Léna C., Bessis A., Lallemand Y., LeNovere N., Vincent P., Pich E.M., Brclet P., and Changeux J.P. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 374 (1995) 65-67
175. Pomerleau O.F. Nicotine as a psychoactive drug: Anxiety and pain reduction. Psychopharmacol. Bull. 22 (1986) 865-869
176. Pratt J., Stolerman I., Garcha H., Giardini V., and Feyerabend C. Discriminative stimulus properties of nicotine: Further evidence for mediation at a cholinergic receptor. Psychopharmacology 81 (1983) 54-60
177. Pugh P., and Berg D. Neuronal acetylcholine receptors that bind α-bungarotoxin mediate neurite retraction in a calcium-dependent manner. J. Neurosci. 14 (1994) 889-896
178. Qian C., Li T., Shen T.Y., Libertine-Garahan L., Eckman J., Biftu T., and Ip S. Epibatidine is a nicotinic analgesic. Eur. J. Pharmacol. 250 (1993) R13-R14
179. Ramirez-Lattore J.A., Qu X., and Role L. Participation of alpha5 in neuronal nicotinic AChR channels. J. Neurosci. 13 (1993) 442-454
180. Ramoa A., Alkondon M., Aracava Y., Irons J., Lunt G., Deshpande S., Wonnacott S., Aronstam R., and Albuquerque E. The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels. J. Pharmacol. Exp. Ther. 254 (1990) 71-82
181. Reavill C., Spivak C., Stolerman I., and Waters J. Isoarecolone can inhibit nicotine binding and produce nicotine-like discriminative stimulus effect in rats. Neuropharmacology 26 (1987) 789-792
182. Reavill C., and Stolerman I.P. Locomotor activity in rats after administration of nicotinic agonists intracerebrally. Br. J. Pharmacol. 99 (1990) 273-278
183. Reavill C., Walther B., Stolerman I., and Testa B. Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology 29 (1990) 619-624
184. Reavill C., Waters J., Stolerman I., and Garcha H. Behavioural effects of the nicotinic agonists N-(3-pyridylmethyl)pyrrolidine and isoarecolone in rats. Psychopharmacology 102 (1990) 521-528
185. Ribeiro E.B., Bettiker R.L., Bogdanov M., and Wurtman R.J. Effects of systemic nicotine on serotonin release in rat brain. Brain Res. 621 (1993) 311-318
186. IA and nicotinic cholinergic receptors in the regulation of water maze navigation behavior. Brain Res. 649 (1994) 174-180
187. Riekkinen Jr. P., Riekkinen M., Sirviö J., and Riekkinen P. Effects of concurrent nicotinic antagonist and PCPA treatments on spatial and passive avoidance learning. Brain Res. 575 (1992) 247-250
188. Riekkinen Jr. P., and Riekkinen M. Effects of tetrahydroaminoacridine and nicotine in nucleus basalis and serotonin-lesioned rats. Eur. J. Pharmacol. 279 (1995) 65-73
189. Riekkinen Jr. P., Sirviö J., and Riekkinen M. Serotonin depletion decreases the therapeutic effect of nicotine, but not THA, in medial septal-lesioned rats. Brain Res. 662 (1994) 95-102
190. Robinson T.E., and Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev. 11 (1986) 157-198
191. Rogers D.T., and Iwamoto E.T. Multiple spinal mediators in parenteral nicotine-induced antinociception. J. Pharmacol. Exp. Therap. 267 (1993) 341-349
192. Romano C., Goldstein A., and Jewell N. Characterization of the receptor mediating the nicotine discriminative stimulus. Psychopharmacology 74 (1981) 310-315
193. Rose J., Behm F., Westman E., Levin E., Stein R., and Ripka G. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharm. Ther. 56 (1994) 86-99
194. Rose J., and Levin E. Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence. Pharmacol. Biochem. Behav. 41 (1991) 219-226
195. Rosecrans J.A., Kallman M., and Glennon R. The nicotine cue: An overview. In: Colpaert F., and Rosecrans J. (Eds). "Stimulus Properties of Drugs: Ten Years of Progress" (1979), Elsevier-North Holland, Amsterdam 69-81
196. Rosecrans J.A., and Chance W.T. Cholinergic and non-cholinergic aspects of the discriminative stimulus properties of nicotine. In: Lal H. (Ed). "Discriminative Stimulus Properties of Drugs" (1977), Plenum Press, New York 155-185
197. Rubboli F., Court J.A., Sala C., Morris C., Chini B., Perry E., and Clementi F. Distribution of nicotinic receptors in human hippocampus and thalamus. Eur. J. Neurosci. 6 (1994) 1596-1604
198. Rusted J., Graupner L., O'Connell N., and Nicholls C. Does nicotine improve cognitive function. Psychopharmacology 115 (1994) 547-549
199. Rusted J.M., and Warburton D.M. Facilitation of memory by post-trial administration of nicotine: Evidence for an attentional explanation. Psychopharmacology 108 (1992) 452-455
200. Sahakian B., Jones G., Levy R., Gray J., and Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer's type. Br. J. Psychiatry 154 (1989) 797-800
201. Sanberg P., McConville B., Fogelson H., Manderscheid P., Parker K., Blythe M., Klykylo W., and Norman A. Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette's syndrome. Biomed. Pharmacother. 43 (1985) 19-23
202. Sargent P.B. The diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Neurosci. 16 (1993) 403-443
203. Schechter M., and Rosecrans J. Nicotine as a discriminative cue in rats: Inability of related drugs to produce the nicotine-like cueing effect. Psychopharmacologia 27 (1972) 379-387
204. Schröder H., Giacobini E., Struble R.G., Zilles K., and Maelicke A. Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol. Aging 12 (1991) 259-262
205. Schulz D., Loring R., Aizenman E., and Zigmond R. Autoradiographic localization of putative nicotinic receptors in the rat brain using ['Z'I]neuronal bungarotoxin. J. Neurosci. 11 (1991) 287-297
206. 3H]acetylcholine in rat brain. Mol. Pharmacol. 22 (1982) 56-62
207. Sequela P., Wadiche J., Dineley-Miller K., Dani J., and Patrick J. Molecular cloning, functional properties, and distribution of rat brain 017: A nicotinic cation channel highly permeable to calcium. J. Neurosci. 13 (1993) 596-604
208. Shader R.I., and Greenblatt D.J. Use of benzodiazepines in anxiety disorders. N. Engl. J. Med. 328 (1993) 1398-1405
209. Shoaib M., Benwell M.E.M., Akbar M.T., Stolerman I.P., and Balfour D.J.K. Behavioural and neurochemical adaptations to nicotine in rats: Influence of NMDA antagonists. Br. J. Pharmacol. 111 (1994) 1073-1080
210. Shoaib M., and Stolerman I.P. Locomotor activity after nicotine infusions into the fourth ventricle of rats. Pharmacol. Biochem. Behav. 48 (1994) 749-754
211. - ion channels modulated by multiple drug-binding sites. Trends Pharmacol. Sci. 13 (1992) 446-450
212. Silver A., and Sanberg P. Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome. Lancet 342 (1993) 182
213. Sjak-Shie N., and Meyer E. Effects of chronic nicotine and pilocarpine administration on neocortical neuronal density and ['HIGABA uptake in nucleus basalis lesioned rats. Brain Res. 624 (1993) 295-298
214. 3H] nicotine to the rat brain P2 preparation. J. Med. Chem. 28 (1985) 1245-1251
215. Smith C., and Giacobini E. Nicotine, Parkinson's and Alzheimer's disease. Rev. Neurosci. 3 (1992) 25-43
216. Stolerman I. Behavioural pharmacology of nicotine: Implications for multiple brain nicotinic receptors. In: Bock G., and Marsh J. (Eds). "The Biology of Nicotine Dependence" (1990), John Wiley & sons, Chichester 3-22
217. Stolerman I. Behavioural pharmacology of nicotine in animals. In: Wonnacot S., Russell M., and Stolerman I. (Eds). "Nicotine Psychopharmacology" (1990), Oxford University Press, Oxford 279-306
218. Stolerman I., and Jarvis M. The scientific case that nicotine is addictive. Psychopharmacology 117 (1995) 2-10
219. Stolerman I.P., Pratt J.A., Garcha H.S., Giardini V., and Kumar R. Nicotine cue in rats analyzed with drugs acting on cholinergic and 5-hydroxytryptamine mechanisms. Neuropharmacology 22 (1983) 1029-1037
220. Stolerman I., Garcha H., Pratt J., and Kumar R. Role of training dose in discrimination of nicotine and related compounds by rats. Psychopharmacology 84 (1984) 413-419
221. Stolerman I.P., Albuquerque E.X., and Garcha H.S. Behavioural effects of anatoxin, a potent nicotinic agonist, in rats. Neuropharmacology 31 (1992) 311-314
222. Stolerman I., Garcha H., and Mirza N. Dissociations between the locomotor stimulant and depressant effects of nicotinic agonists in rats. Psychopharmacology 117 (1995) 430-437
223. Stroud R.M., McCarthy M.P., and Shuster M. Nicotinic acetylcholine receptor superfamily of ligand-gated channels. Biochemistry 29 (1990) 11009-11023
224. Sullivan J.P., Briggs C., Donnelly-Roberts D., Brioni J., Radek R., McKenna D., Campbell J., Arneric S., Decker M., and Bannon A. (±)-Epibatidine can differentially evoke responses mediated by putative subtypes of nicotinic acetylcholine receptors (nAChRs). Med. Chem. Res. 4 (1994) 502-516
225. Sullivan J.P., Decker M.W., Brioni J.D., Donnelly-Roberts D., Anderson D.J., Bannon A.W., Kang C., Adams P., Piattoni-Kaplan M., Buckley M.J., Gopalakrishnan M., Williams M., and Arneric S.P. (±)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 271 (1994) 624-631
226. Sullivan J.P., Donnelly-Roberts D., Anderson D.J., Gopalakrishnan M., Briggs C.A., Campbell J.E., Piattoni-Campbell M., McKenna D.G., Molinari E., Holladay M.W., Lin N.-H., and Arneric S.P. A-85380 [3-(2(S)-azetidinylmethoxy) pyridine: In vitro pharmacological properties of a novel 50 pM affinity cholinergic channel ligand. Neuropharmacology (1996) In press
227. Taylor P. Agents acting at the neuromuscular junction and autonomic ganglia. In: Goodman-Gilman A., Rall T., Nies A., and Taylor P. (Eds). "The Pharmacological Basis of Therapeutics,". 8th ed. (1990), Pergamon Press, New York 166-186
228. Taylor P. Cholinergic agonists. In: Goodman-Gilman A., Rall T., Nies A., and Taylor P. (Eds). "The Pharmacological Basis of Therapeutics,". 8th ed. (1990), Pergamon Press, New York 122-130
229. Terry Jr. A.V., Buccafusco J.J., and Jackson W.J. Scopolamine reversal of nicotine enhanced delayed matching-to-sample performance in monkeys. Pharmacol. Biochem. Behav. 45 (1993) 925-929
230. Thomas P., Stephens M., Wilkie G., Amar M., Lunt G., Whiting P., Gallaher T., Pereira E., Alkondon M., Albuquerque E.X., and Wonnacott S. (+)-Anatoxin-A is a potent agonist at neuronal nicotinic acetylcholine receptors. J. Neurochem. 60 (1993) 2308-2311
231. Treinin M., and Chalfie M. A mutated acetylcholine receptor subunit causes neuronal degeneration in C Elegans. Neuron 14 (1995) 871-877
232. Turchi J., Holley L., and Sarter M. Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats. Psychopharmacology 118 (1995) 195-205
233. US Department of Health and Human Services, P. H. S., Office on Smoking and Health. (1988). The health consequences of smoking: Nicotine addiction. A report of the Surgeon General.
234. Valera S., Ballivet M., and Bertrand D. Progesterone modulates a neuronal nicotinic acetylcholine receptor. Proc. Natl. Acad. Sci. USA 89 (1992) 9949-9953
235. Vernino S., Amador M., Luetje C.W., Patrick J., and Dani J.A. Calcium modulation and high calcium permeability of neuronal nicotinic acetylcholine receptors. Neuron 8 (1992) 127-134
236. Vezina P., Hervé D., Glowinski J., and Tassin J.P. Injections of 6-hydroxydopamine into the ventral tegmental area destroy mesolimbic dopamine neurons but spare the locomotor activating effects of nicotine in the rat. Neurosci. Lett. 168 (1994) 111-114
237. Vijayaraghavan S., Huang B., Blumenthal E., and Berg D. Arachidonic acid as a possible negative feedback inhibitor of nicotinic acetylcholine receptors on neurons. J. Neurosci. 15 (1995) 3679-3687
238. 2+. Neuron 8 (1992) 353-362
239. Wada E., McKinnon D., Heinemann S., Patrick J., and Swanson L.W. The distribution of mRNA encoded by a new member of the neuronal nicotinic acetylcholine receptor gene family α5) in the rat central nervous system. Brain Res. 526 (1990) 45-53
240. Wada E., Wada K., Boulter J., Deneris E., Heinemann S., Patrick J.W., and Swanson L.W. Distribution of alpha-2, alpha-3, alpha-4, and beta-2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: A hybridization histochemical study in the rat. J. Comp. Neurol. 284 (1989) 314-335
241. Warburton D.M., and Arnall C. Improvements in performance without nicotine withdrawal. Psychopharmacology 115 (1994) 539-540
242. Warburton D.M., Rusted J.M., and Fowler J. A comparison of the attentional and consolidation hypotheses for the facilitation of memory by nicotine. Psychopharmacology 108 (1992) 443-447
243. Welzl H., Bättig K., and Berz S. Acute effects of nicotine injection into the nucleus accumbens on locomotor activity in nicotine-naive and nicotine-tolerant rats. Pharmacol. Biochem. Behav. 37 (1990) 743-776
244. Westfall T.C., Fleming R.M., Fudger M.F., and Clark W.G. Effect of nicotine and related substances upon amine levels in the brain. Ann. NY Acad. Sci. 142 (1967) 83-100
245. Wevers A., Jeske A., Lobron C., Birtsch C., Heinemann S., Schroder R., and Schroder H. Cellular distribution of nicotinic acetylcholine receptor subunit mRNAs in the human cerebral cortex as revealed by non-isotopic in situ hybridization. Mol. Brain Res. 25 (1994) 122-128
246. 3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease. Neurology 38 (1988) 720-723
247. Whitehouse P.J., Martino A., Antuono P., Lowenstein P., Coyle J., Price D., and Kellar K. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 371 (1986) 146-151
248. Whiting P., Schoepfer R., Lindstrom J., and Priestly T. Structural and pharmacological characterization of the major brain nicotinic acetylcholine receptor subtype stably expressed in mouse fibroblasts. Mol. Pharmacol. 40 (1992) 463-472
249. Wilkie G.I., Hutson P.H., Stephens M.W., Whiting P., and Wonnacott S. Hippocampal nicotinic autoreceptors modulate acetylcholine release. Biochem. Soc. Trans. 21 (1993) 429-431
250. Williams M., and Robinson J.L. Binding of the nicotinic cholinergic antagonist dihydro-beta-erythroidine in rat brain tissue. J. Neurosci. 4 (1984) 2906-2911
251. Williams M., Sullivan J., and Arneric S. Neuronal nicotinic acetylcholine receptors. Drug News Perspect. 7 (1994) 205-223
252. Wilson A., Langley L., Monley J., Bauer T., Rottunda S., McFalls E., Kovera C., and McCarten J. Nicotine patches in Alzheimer's disease: Pilot study on learning, memory and safety. Pharmacol. Biochem. Behav. 51 (1995) 509-514
253. Wolf M.E., and Khansa M.R. Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine. Brain Res. 562 (1991) 291-294
254. Wong E., Holstad S., Mennerick S., Hong S., Zorumski C., and Isenberg K. Pharmacological and physiological properties of a putative ganglionic nicotinic receptor, α3β4, expressed in transfected eucaryotic cells. Mol. Brain Res. 28 (1995) 101-109
255. Wonnacott S., Albuquerque E.X., and Bertrand D. Methyllycaconitine: A new probe that discriminates between nicotinic acetylcholine receptor subclasses. Methods Neurosci. 12 (1993) 263-275
256. Wonnacott S., Drasdo A., Sanderson E., and Rowell P. Presynaptic nicotinic receptors and the modulation of transmitter release. In: Bock G., and Marsh J. (Eds). "The Biology of Nicotine Dependence" (1990), John Wiley & Sons Ltd, Chichester 87-101
257. Wonnacott S., Fryer L., Lunt G., Freund R., Jungschaffer D., and Collins A. Nicotinic modulation of GABAergic neurotransmission in the hippocampus. Soc. Neurosci. Abstr. 17 (1987) 1352
258. Wonnacott S., Irons J., Rapier C., Thorne B., and Lunt G.G. Presynaptic modulation of transmitter release by nicotinic receptors. In: Norberg A., Fuxe K., Holmstedt B., and Sundwall A. (Eds). "Progress in Brain Research" (1990), Elsevier, Amsterdam 157-163
259. Wonnacott S., Jackman J.L., Swanson K.L., Rapoport H., and Albuquerque E.X. Nicotinic pharmacology of anatoxin analogs II. Side chain structure-activity relationships at neuronal nicotinic ligand binding sites. J. Pharmacol. Exp. Ther. 259 (1991) 387-391
260. Wonnacott S., Wilkie G., Soliakov L., and Whiteaker P. Presynaptic nicotinic autore-ceptors and heteroreceptors in the CNS. In: Clarke P.B.S., Quik M., Adlkofer F., and Thurau K. (Eds). "Effects of Nicotine on Biological Systems 11" (1995), Birkhauser Verlag, Basel 87-94
261. Woodruff-Pak D.S., Li Y.-T., and Kem W.R. A nicotinic agonist (GTS-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res. 645 (1994) 309-317
262. Yost C., and Dodson B. Inhibition of the nicotinic acetylcholine receptor by barbiturates and by procaine: Do they act at different sites. Cell Mol. Neurobiol. 13 (1993) 159-172